Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
duval cibmtr score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Score 00–0
  • Score 11–1
  • Score 22–2
  • Score ≥33–5
Direct Clinical Answer

The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival calculator is designed for bedside predicting transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors in clinical practice. The resulting score directly guides clinician decision-making regarding initiating.

Clinical Guidelines & Evidence

Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.

Clinical Indication

The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival is indicated for bedside clinical practice to support Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Reduced-intensity conditioning, syngeneic, and cord blood transplants were excluded from the original study..

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Only busulfan and TBI-based myeloablative conditioning regimens were studied in the original validation..

Formula & Variables:

Score = disease_group_points + cytogenetics_points + hla_match_points + circulating_blasts_points + karnofsky_points. Total score ranges from 0-5 points with lower scores indicating better prognosis.

Input Parameters

NameTypeRequiredDescription
disease_groupstringYesDisease status at time of transplantation
cytogeneticsstringYesCytogenetic risk category prior to HSCT
hla_match_groupstringYesHLA matching status between donor and recipient
circulating_blastsstringYesPresence of circulating blasts at time of transplantation
karnofsky_lansky_scalestringYesKarnofsky (adults) or Lansky (pediatric) performance status scale

Score Interpretation & Guidance

RangeStageDescription
0–0Score 0Excellent prognosis
1–1Score 1Good prognosis
2–2Score 2Intermediate prognosis
3–5Score ≥3Poor prognosis

Evidence-Based References (EBM)

  • Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852.DOI: 10.1200/JCO.2010.28.8852
  • Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacytidine vs physicians' choice as maintenance therapy for patients with AML in first remission after intensive chemotherapy ineligible for stem cell transplantation. Blood. 2013;121(24):4906-14.
  • Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-1.
  • Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-90. doi: 10.1038/nrclinonc.2012.150.DOI: 10.1038/nrclinonc.2012.150

Related calculators